LCM
AUTL

Laurion Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Laurion Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.31M Hold
3,316,626
– – 0.14% 135
2026
Q1 		$4.58M Hold
3,316,626
– – 0.2% 140
2025
Q4 		$6.6M Hold
3,316,626
– – 0.25% 67
2025
Q3 		$5.41M Hold
3,316,626
– – 0.09% 127
2025
Q2 		$7.56M Sell
3,316,626
-52,622
-2% -$87K 0.14% 115
2025
Q1 		$5.22M Buy
3,369,248
+179,701
+6% +$365K 0.13% 104
2024
Q4 		$7.5M Hold
3,189,547
– – 0.14% 114
2024
Q3 		$11.6M Sell
3,189,547
-456,683
-13% -$1.82M 0.16% 67
2024
Q2 		$12.7M Buy
3,646,230
+1,555,759
+74% +$6.71M 0.15% 101
2024
Q1 		$13.3M Buy
2,090,471
+1,205,000
+136% +$7.52M 0.11% 159
2023
Q4 		$5.7M Sell
885,471
-590,635
-40% -$2.25M 0.05% 234
2023
Q3 		$3.44M Sell
1,476,106
-23,894
-2% -$68.1K 0.02% 303
2023
Q2 		$3.57M Hold
1,500,000
– – 0.02% 280
2023
Q1 		$2.76M Hold
1,500,000
– – 0.02% 262
2022
Q4 		$2.85M Buy
+1,500,000
New +$3.79M 0.01% 293
2021
Q2 		– Sell
-152,847
Closed -$876K – 704
2021
Q1 		$876K Buy
+152,847
New +$1.13M ﹤0.01% 520
2020
Q3 		– Sell
-67,519
Closed -$1.08M – 836
2020
Q2 		$1.08M Sell
67,519
-51,215
-43% -$568K 0.01% 410
2020
Q1 		$711K Buy
+118,734
New +$1.1M 0.01% 540
2019
Q3 		– Sell
-45,314
Closed -$730K – 1004
2019
Q2 		$730K Buy
+45,314
New +$1.01M 0.01% 619
2018
Q4 		– Sell
-24,190
Closed -$730K – 1099
2018
Q3 		$730K Sell
24,190
-50,810
-68% -$1.37M 0.01% 750
2018
Q2 		$2.01M Buy
+75,000
New +$1.98M 0.02% 604

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Laurion Capital Management's AUTL Position: Q2 2026 in Review

Laurion Capital Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 3,316,626 shares worth $5.31M. The position accounts for 0.14% of the portfolio, ranked #135.

Laurion Capital Management first reported a position in AUTL in Q2 2018 and has held it in 21 quarters since. The position peaked at $13.3M in Q1 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Laurion Capital Management held 3,316,626 shares of Autolus Therapeutics worth $5.31M as of Q2 2026.
  • Laurion Capital Management left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up 0.14% of Laurion Capital Management's portfolio in Q2 2026, its #135 holding.
  • Laurion Capital Management first reported a position in Autolus Therapeutics in Q2 2018 and has held it in 21 quarters since.
  • Laurion Capital Management's Autolus Therapeutics position peaked at $13.3M in Q1 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Laurion Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.